<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03028129</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1189-0829</org_study_id>
    <nct_id>NCT03028129</nct_id>
  </id_info>
  <brief_title>Prevention of Tuberculosis in Prisons</brief_title>
  <official_title>Primary Prophylaxis for Prevention of TB in Prison's Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Mato Grosso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Mato Grosso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the isoniazid is effective in the prevention of
      tuberculosis in a prison population, exposed to the high endemicity of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite being a known disease of mankind over 9000 years, tuberculosis (TB) is still a major
      public health problem in developing countries, mainly due to so-called highly endemic sites,
      such as prisons.

      It is Infectious disease, with airborne transmission, TB can present both the active or
      latent form. Despite the biological aspect of transmission, unhealthy environmental
      conditions (room without direct sunlight, poor ventilation and overcrowded) and individual
      factors (malnutrition, immunosuppression, use of alcohol and other drugs) have significant
      influence on transferability and infectivity.

      With the discovery of drugs active against Mycobacterium tuberculosis, it was observed a
      reduction of disease incidence in the world. Despite this declining incidence, World Health
      Organization (WHO) classifies TB as a public health problem due to the emergence of multidrug
      strains or extensively resistant to treatment, added to the cases of latent TB reactivation,
      observed with the advent of HIV/AIDS.

      Studies show a direct relationship between the incidence of TB and the prison environment.
      Nevertheless, the presence of prisons in one location increases the incidence of this
      disease, indicating that there is an exchange of disease between the prison and the
      community.

      Currently, control of TB in the prison system is based on the tracking of individuals with
      active TB and / or latent and, in their respective treatment. For the identification of
      individuals with active disease, it is necessary the recognition of respiratory symptoms
      (cough mainly) and sputum smear microscopy and sputum culture, and chest X-ray. As the search
      of individuals with latent form, must be carried to the skin test with Purified Protein
      Derived (PPD).

      Most of the units of the Brazilian's prison system these diagnostic methods are not available
      and hence the transport of individuals for their realization is necessary, generating an
      additional cost, in most cases, unfeasible process execution.

      With the completion of this study, it seek to determine the effectiveness of primary
      prophylaxis in the prison population in order to gather new scientific evidence, to bring
      affordable methods for the control of TB in prisons.

      Despite advances in diagnosis and treatment TB, this is the third leading cause of death from
      infectious diseases worldwide (Naghavi et al, 2015). In 2015, the WHO estimated incidence of
      9.6 million new cases of TB in the world, with about 1.1 million deaths. For Brazil it was
      estimated incidence of 44 cases per 100,000 (WHO, 2015). The incidence of TB has declined
      about 2% per year, but this rate is not homogeneous in the global context.

      Brazil occupies the 22nd place in the ranking of the WHO with an estimated annual rate of
      83,310 cases of the disease (Zumla et al, 2015). In the past seven years, it is estimated
      that the incidence declined only 0.7% (per year). A key factor in this slow progress in TB
      control in Brazil, and other emerging countries is the existence of high-risk subpopulations,
      including slums and prisons, which act as reservoirs and amplifiers for the transmission of
      the disease (Basu; Stückler; Mckee 2011; Dowdy et al, 2012). A recent systematic review
      showed that the average incidence of TB in the prison population can be up to 23 times that
      recorded in the general population (Baussano et al, 2010).

      With the fourth largest prison populations in the world, is observed in Brazil, the increased
      incidence of TB among prisoners in the last seven years. Although prisoners represent only
      0.3% of the population, the increase in the prison population over this period resulted in
      almost doubling the proportion of all TB cases that occur among prisoners (4.1% in 2007, 8,
      1% in 2013).

      The arrests are in an ideal environment for the spread of TB, since they show individuals
      users of tobacco and alcohol in high doses, in addition to drug abuse in overcrowded cells
      with poor ventilation and with limited access to care health and diagnosis of TB. Currently,
      the Ministry of Health recommends active search for TB at the entrance to the prison and once
      a year by chest X-ray. Due to the cost and logistics, most prisons do not adhere to this
      recommendation. There is also a clear recommendation not to use the tuberculin skin test or
      perform the treatment for latent tuberculosis. If the procedures for active case detection
      and / or prophylactic treatment would impact the high transmission in prisons is a question
      that still remains open (Al-Darraji; Kamarulzamn; Altice, 2012).

      The concentration of cases of TB in prisons can represent both an obstacle and an opportunity
      to control the disease, depending on the effectiveness of interventions in these
      environments.

      Preliminary studies show high annual rate of TB infection (26%) among the prison population
      of 12 penitentiaries of Mato Grosso do Sul. Besides the large burden of disease in this
      population is significant dispersion of the TB prison to the community (Sacchi et al, 2015).
      Cross-sectional studies show high yield annual screening for TB, however, the effectiveness
      of this measure combined with other interventions remains unclear (Ferreira et al, 1996;
      Fournet et al, 2006; Lemos et al, 2014; Vieira et al, 2010; Sanches et al, 2013; Walnut;
      Abrahão; Galesi, 2012; Kuhleis et al, 2012; Estevan; Oliveira; Croda, 2013). Due to the
      combination of high force of infection in prisons and short prison term, primary prophylaxis
      may be an effective intervention. This new approach has never been evaluated in the context
      of prisons in low and middle income countries; to assess the impact of program strategies for
      TB screening and prophylaxis, longitudinal data will be essential. Given the infrastructure
      that was created for long-term prospective studies in Brazil, there is an excellent
      opportunity to close the critical knowledge gaps that have been barriers to effective
      implementation of TB control in high transmission prisons.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis showed efficacy less than 2.5%.
  </why_stopped>
  <start_date type="Actual">September 4, 2017</start_date>
  <completion_date type="Actual">August 10, 2019</completion_date>
  <primary_completion_date type="Actual">August 10, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantiferon TB Gold Plus (QIAGEN®) Conversion at the Premature Exclusion Visit.</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Number of participants who had a Quantiferon TB Gold Plus (QIAGEN®) score greater than or equal to 0.35 international units per milliliter, at the time of the premature exclusion visit, on all participants in the group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">467</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>Antibiotic Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid 900 milligrams</intervention_name>
    <description>Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Antibiotic Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Placebo Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age above 18 and under 45 at the time of inclusion;

          -  Sign the informed consent form.

        Exclusion criteria:

          -  Be indigenous;

          -  Active TB or previous use of isoniazid;

          -  Score Alcohol Use Disorders Identification Test ≥15.

          -  Reactive serology for HIV, hepatitis B and C;

          -  Reactive result for quantiferon, considering as positive the result of Tube 1 and / or
             Tube22 above 0.2 IU / mL;

          -  Liver enzymes (Aspartate aminotransferase and Alanate aminotransferase) three times
             the upper limit;

          -  History or treatment for epilepsy;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flora MF Moreira, Graduate</last_name>
    <role>Study Chair</role>
    <affiliation>MsC Student</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea SS Carbone, MsC</last_name>
    <role>Study Chair</role>
    <affiliation>PhD Student</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flavia PC Sacchi, MsC</last_name>
    <role>Study Chair</role>
    <affiliation>PhD Student</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paulo CP Santos, Graduate</last_name>
    <role>Study Chair</role>
    <affiliation>MsC Student</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafaele CP Araújo, MsC</last_name>
    <role>Study Chair</role>
    <affiliation>PhD Student</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandra C Leite, MsC</last_name>
    <role>Study Chair</role>
    <affiliation>PhD Student</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cassia B Reis, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Pos doc Student</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valeria C Rolla, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason R Andrews, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roberto Oliveira</name>
      <address>
        <city>Dourados</city>
        <state>Mato Grosso Do Sul</state>
        <zip>78824210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.prisonstudies.org/country/brazil</url>
    <description>World Prison Brief: Brazil.</description>
  </link>
  <link>
    <url>https://www.sealedenvelope.com/power/binary-superiority</url>
    <description>Power calculator for binary outcome superiority trial.</description>
  </link>
  <link>
    <url>http://www.who.int/gho/tb/epidemic/cases_deaths/en/#</url>
    <description>Global Health Observatory (GHO) data</description>
  </link>
  <reference>
    <citation>Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR Jr. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994 Jan 14;263(5144):227-30.</citation>
    <PMID>8284673</PMID>
  </reference>
  <reference>
    <citation>Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009 Dec;7(12):845-55. doi: 10.1038/nrmicro2236. Epub 2009 Oct 26. Review.</citation>
    <PMID>19855401</PMID>
  </reference>
  <reference>
    <citation>Basu S, Stuckler D, McKee M. Addressing institutional amplifiers in the dynamics and control of tuberculosis epidemics. Am J Trop Med Hyg. 2011 Jan;84(1):30-7. doi: 10.4269/ajtmh.2011.10-0472.</citation>
    <PMID>21212197</PMID>
  </reference>
  <reference>
    <citation>Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis incidence in prisons: a systematic review. PLoS Med. 2010 Dec 21;7(12):e1000381. doi: 10.1371/journal.pmed.1000381. Review.</citation>
    <PMID>21203587</PMID>
  </reference>
  <reference>
    <citation>BERNSTEIN J, LOTT WA, STEINBERG BA, YALE HL. Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds. Am Rev Tuberc. 1952 Apr;65(4):357-64.</citation>
    <PMID>14903503</PMID>
  </reference>
  <reference>
    <citation>Brites D, Gagneux S. Old and new selective pressures on Mycobacterium tuberculosis. Infect Genet Evol. 2012 Jun;12(4):678-85. doi: 10.1016/j.meegid.2011.08.010. Epub 2011 Aug 17. Review.</citation>
    <PMID>21867778</PMID>
  </reference>
  <reference>
    <citation>Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, Eiglmeier K, Garnier T, Gutierrez C, Hewinson G, Kremer K, Parsons LM, Pym AS, Samper S, van Soolingen D, Cole ST. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3684-9. Epub 2002 Mar 12.</citation>
    <PMID>11891304</PMID>
  </reference>
  <reference>
    <citation>Carbone Ada S, Paião DS, Sgarbi RV, Lemos EF, Cazanti RF, Ota MM, Junior AL, Bampi JV, Elias VP, Simionatto S, Motta-Castro AR, Pompílio MA, de Oliveira SM, Ko AI, Andrews JR, Croda J. Active and latent tuberculosis in Brazilian correctional facilities: a cross-sectional study. BMC Infect Dis. 2015 Jan 22;15:24. doi: 10.1186/s12879-015-0764-8.</citation>
    <PMID>25608746</PMID>
  </reference>
  <reference>
    <citation>Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, Yeboah-Manu D, Bothamley G, Mei J, Wei L, Bentley S, Harris SR, Niemann S, Diel R, Aseffa A, Gao Q, Young D, Gagneux S. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013 Oct;45(10):1176-82. doi: 10.1038/ng.2744. Epub 2013 Sep 1.</citation>
    <PMID>23995134</PMID>
  </reference>
  <reference>
    <citation>Dowdy DW, Golub JE, Chaisson RE, Saraceni V. Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9557-62. doi: 10.1073/pnas.1203517109. Epub 2012 May 29.</citation>
    <PMID>22645356</PMID>
  </reference>
  <reference>
    <citation>Estevan AO, Oliveira SM, Croda J. Active and latent tuberculosis in prisoners in the Central-West Region of Brazil. Rev Soc Bras Med Trop. 2013 Jul-Aug;46(4):515-8.</citation>
    <PMID>23904084</PMID>
  </reference>
  <reference>
    <citation>Ferreira MM, Ferrazoli L, Palaci M, Salles PS, Medeiros LA, Novoa P, Kiefer CR, Schechtmann M, Kritski AL, Johnson WD, Riley LW, Ferreira Júnior OC. Tuberculosis and HIV infection among female inmates in São Paulo, Brazil: a prospective cohort study. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Oct 1;13(2):177-83.</citation>
    <PMID>8862283</PMID>
  </reference>
  <reference>
    <citation>Fournet N, Sanchez A, Massari V, Penna L, Natal S, Biondi E, Larouzé B. Development and evaluation of tuberculosis screening scores in Brazilian prisons. Public Health. 2006 Oct;120(10):976-83. Epub 2006 Sep 11.</citation>
    <PMID>16965796</PMID>
  </reference>
  <reference>
    <citation>FOX HH. The chemical approach to the control of tuberculosis. Science. 1952 Aug 8;116(3006):129-34.</citation>
    <PMID>14950210</PMID>
  </reference>
  <reference>
    <citation>Hanson ML, Comstock GW, Haley CE. Community isoniazid prophylaxis program in an underdeveloped area of Alaska. Public Health Rep. 1967 Dec;82(12):1045-56.</citation>
    <PMID>4966218</PMID>
  </reference>
  <reference>
    <citation>Hershkovitz I, Donoghue HD, Minnikin DE, Besra GS, Lee OY, Gernaey AM, Galili E, Eshed V, Greenblatt CL, Lemma E, Bar-Gal GK, Spigelman M. Detection and molecular characterization of 9,000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLoS One. 2008;3(10):e3426. doi: 10.1371/journal.pone.0003426. Epub 2008 Oct 15.</citation>
    <PMID>18923677</PMID>
  </reference>
  <reference>
    <citation>Kuhleis D, Ribeiro AW, Costa ER, Cafrune PI, Schmid KB, Costa LL, Ribeiro MO, Zaha A, Rossetti ML. Tuberculosis in a southern Brazilian prison. Mem Inst Oswaldo Cruz. 2012 Nov;107(7):909-15.</citation>
    <PMID>23147148</PMID>
  </reference>
  <reference>
    <citation>Lemos EF, Alves AM, Oliveira Gde C, Rodrigues MP, Martins ND, Croda J. Health-service performance of TB treatment for indigenous and non-indigenous populations in Brazil: a cross-sectional study. BMC Health Serv Res. 2014 May 23;14:237. doi: 10.1186/1472-6963-14-237.</citation>
    <PMID>24885134</PMID>
  </reference>
  <reference>
    <citation>MacIntyre CR, Kendig N, Kummer L, Birago S, Graham NM. Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons. Clin Infect Dis. 1997 Jun;24(6):1060-7.</citation>
    <PMID>9195058</PMID>
  </reference>
  <reference>
    <citation>Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011 Jul 7;365(1):11-20. doi: 10.1056/NEJMoa1005136.</citation>
    <PMID>21732833</PMID>
  </reference>
  <reference>
    <citation>GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18.</citation>
    <PMID>25530442</PMID>
  </reference>
  <reference>
    <citation>Nerlich AG, Haas CJ, Zink A, Szeimies U, Hagedorn HG. Molecular evidence for tuberculosis in an ancient Egyptian mummy. Lancet. 1997 Nov 8;350(9088):1404.</citation>
    <PMID>9365482</PMID>
  </reference>
  <reference>
    <citation>Nguyen L, Pieters J. Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: challenges in tuberculosis drug development. Annu Rev Pharmacol Toxicol. 2009;49:427-53. doi: 10.1146/annurev-pharmtox-061008-103123. Review.</citation>
    <PMID>19281311</PMID>
  </reference>
  <reference>
    <citation>Nogueira PA, Abrahão RM, Galesi VM. Tuberculosis and latent tuberculosis in prison inmates. Rev Saude Publica. 2012 Feb;46(1):119-27. Epub 2011 Dec 13.</citation>
    <PMID>22252791</PMID>
  </reference>
  <reference>
    <citation>Sacchi FP, Praça RM, Tatara MB, Simonsen V, Ferrazoli L, Croda MG, Suffys PN, Ko AI, Andrews JR, Croda J. Prisons as reservoir for community transmission of tuberculosis, Brazil. Emerg Infect Dis. 2015 Mar;21(3):452-5. doi: 10.3201/eid2103.140896.</citation>
    <PMID>25642998</PMID>
  </reference>
  <reference>
    <citation>Salpeter SR. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med. 1993 Nov;159(5):560-4.</citation>
    <PMID>8279152</PMID>
  </reference>
  <reference>
    <citation>Sanchez A, Massari V, Gerhardt G, Espinola AB, Siriwardana M, Camacho LA, Larouzé B. X ray screening at entry and systematic screening for the control of tuberculosis in a highly endemic prison. BMC Public Health. 2013 Oct 20;13:983. doi: 10.1186/1471-2458-13-983.</citation>
    <PMID>24139204</PMID>
  </reference>
  <reference>
    <citation>Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013 Jul 5;(7):CD007545. doi: 10.1002/14651858.CD007545.pub2. Review.</citation>
    <PMID>23828580</PMID>
  </reference>
  <reference>
    <citation>Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;(2):CD001363. Review.</citation>
    <PMID>10796642</PMID>
  </reference>
  <reference>
    <citation>Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, Musser JM. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9869-74.</citation>
    <PMID>9275218</PMID>
  </reference>
  <reference>
    <citation>Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins MD, Aziz MA, Pai M. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006 Oct;6(10):664-74. Review.</citation>
    <PMID>17008175</PMID>
  </reference>
  <reference>
    <citation>Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.</citation>
    <PMID>22150035</PMID>
  </reference>
  <reference>
    <citation>Temple ME, Nahata MC. Rifapentine: its role in the treatment of tuberculosis. Ann Pharmacother. 1999 Nov;33(11):1203-10. Review.</citation>
    <PMID>10573321</PMID>
  </reference>
  <reference>
    <citation>THOREN M, HINSHAW HC. Therapy of pulmonary tuberculosis with isoniazid alone and in combination with streptomycin and with para-amino-salicylic acid. Stanford Med Bull. 1952 Nov;10(4):316-8.</citation>
    <PMID>13015302</PMID>
  </reference>
  <reference>
    <citation>Urrego J, Ko AI, da Silva Santos Carbone A, Paião DS, Sgarbi RV, Yeckel CW, Andrews JR, Croda J. The Impact of Ventilation and Early Diagnosis on Tuberculosis Transmission in Brazilian Prisons. Am J Trop Med Hyg. 2015 Oct;93(4):739-46. doi: 10.4269/ajtmh.15-0166. Epub 2015 Jul 20.</citation>
    <PMID>26195459</PMID>
  </reference>
  <reference>
    <citation>Vieira AA, Ribeiro SA, de Siqueira AM, Galesi VM, dos Santos LA, Golub JE. Prevalence of patients with respiratory symptoms through active case finding and diagnosis of pulmonary tuberculosis among prisoners and related predictors in a jail in the city of Carapicuíba, Brazil. Rev Bras Epidemiol. 2010 Dec;13(4):641-50.</citation>
    <PMID>21180853</PMID>
  </reference>
  <reference>
    <citation>Zumla A, George A, Sharma V, Herbert RH; Baroness Masham of Ilton, Oxley A, Oliver M. The WHO 2014 global tuberculosis report--further to go. Lancet Glob Health. 2015 Jan;3(1):e10-2. doi: 10.1016/S2214-109X(14)70361-4.</citation>
    <PMID>25539957</PMID>
  </reference>
  <reference>
    <citation>Al-Darraji HA, Kamarulzaman A, Altice FL. Isoniazid preventive therapy in correctional facilities: a systematic review. Int J Tuberc Lung Dis. 2012 Jul;16(7):871-9. doi: 10.5588/ijtld.11.0447. Epub 2012 Mar 7. Review.</citation>
    <PMID>22410101</PMID>
  </reference>
  <reference>
    <citation>Barrera, L. The basics of clinical bacteriology Tuberculosis (2007): 93-112.</citation>
  </reference>
  <reference>
    <citation>Daniel TM. The history of tuberculosis. Respir Med. 2006 Nov;100(11):1862-70. Epub 2006 Sep 1.</citation>
    <PMID>16949809</PMID>
  </reference>
  <reference>
    <citation>Porter JD, McAdam KP. The re-emergence of tuberculosis. Annu Rev Public Health. 1994;15:303-23. Review.</citation>
    <PMID>8054087</PMID>
  </reference>
  <reference>
    <citation>Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol. 2005 Oct;5(10):819-26. Review.</citation>
    <PMID>16200083</PMID>
  </reference>
  <reference>
    <citation>Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):679-91. Review.</citation>
    <PMID>9517576</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <results_first_submitted>September 3, 2019</results_first_submitted>
  <results_first_submitted_qc>October 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2019</results_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Mato Grosso</investigator_affiliation>
    <investigator_full_name>Roberto D Oliveira</investigator_full_name>
    <investigator_title>PhD Student</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Primary prevention</keyword>
  <keyword>Prisoners</keyword>
  <keyword>Controlled Clinical Trial</keyword>
  <keyword>Isoniazid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03028129/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03028129/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible participants were interviewed for eligibility criteria (age, race, alcohol use, comorbidities) and laboratory tests (HIV, hepatitis B and C, liver enzymes, interferon gamma dosing for tuberculosis antigens and active tuberculosis).</recruitment_details>
      <pre_assignment_details>Study was discontinued at ninth month after interim analysis and showed efficacy in intervention group less than 2.5%</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Each subject received two weekly supervised oral doses of placebo, without the active ingredient, similar in size, weight, color, taste and odor.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least one dose of isoniazid or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="258"/>
            <count group_id="B2" value="209"/>
            <count group_id="B3" value="467"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="6.7"/>
                    <measurement group_id="B2" value="29.0" spread="7.1"/>
                    <measurement group_id="B3" value="29.1" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quantiferon TB Gold Plus (QIAGEN®) Conversion at the Premature Exclusion Visit.</title>
        <description>Number of participants who had a Quantiferon TB Gold Plus (QIAGEN®) score greater than or equal to 0.35 international units per milliliter, at the time of the premature exclusion visit, on all participants in the group.</description>
        <time_frame>up to 6 months</time_frame>
        <population>All participants who received at least one dose of isoniazid or placebo and who had blood sample collected to QFT examination at premature exclusion visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).</description>
          </group>
        </group_list>
        <measure>
          <title>Quantiferon TB Gold Plus (QIAGEN®) Conversion at the Premature Exclusion Visit.</title>
          <description>Number of participants who had a Quantiferon TB Gold Plus (QIAGEN®) score greater than or equal to 0.35 international units per milliliter, at the time of the premature exclusion visit, on all participants in the group.</description>
          <population>All participants who received at least one dose of isoniazid or placebo and who had blood sample collected to QFT examination at premature exclusion visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <desc>On the intervention days, all participants were asked about the presence of any unusual signs and / or symptoms. Data were recorded in a log containing start and end date, event description, degree and intervention performed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated SGOT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="258"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="258"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="258"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Flu syndrome</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="258"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="258"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="258"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="258"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="258"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="258"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Loss to follow-up Interruption of the study Arms presented differential group allocation Statistical power to detect the primary endpoint was 73%, lower than estimated in our sample size calculation</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Julio Croda</name_or_title>
      <organization>Federal University of Mato Grosso do Sul</organization>
      <phone>+5567981229959</phone>
      <email>julio.croda@ufms.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

